Undisclosed KAT6A/B inhibitor / Bayer - LARVOL DELTA

Development of a new class of KAT6A/B inhibitors with in vivo efficacy (AACR 2026) - "These inhibitors were first identified via high-throughput screening and subsequently refined through computational modelling and co-crystallization studies. The lead compound from this series, BAY-184, demonstrated efficacy in an in vivo proof-of-concept experiment, confirming its potential as a tool for targeting KAT6A/B activity."

Preclinical • Breast Cancer • Oncology • Solid Tumor • KAT6A • KAT6B